Stockscreener 앱 받기
4.61
0.65%
-0.03
시간 외 거래:
4.55
-0.06
-1.30%
전일 마감가:
$4.64
열려 있는:
$4.65
하루 거래량:
334.74K
Relative Volume:
0.71
시가총액:
$272.40M
수익:
$192.64M
순이익/손실:
$2.51M
주가수익비율:
87.98
EPS:
0.0524
순현금흐름:
$12.42M
1주 성능:
-2.54%
1개월 성능:
+9.50%
6개월 성능:
-10.14%
1년 성능:
-9.25%
1일 변동 폭
$4.565
$4.71
1주일 범위
$4.54
$4.92
52주 변동 폭
$3.8092
$5.545
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
명칭
Vanda Pharmaceuticals Inc
전화
202-734-3400
주소
2200 PENNSYLVANIA AVE NW, WASHINGTON
VNDA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.61 | 274.17M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-31 | 개시 | H.C. Wainwright | Buy |
| 2024-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-05-12 | 개시 | BofA Securities | Buy |
| 2021-01-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-03-16 | 다운그레이드 | Oppenheimer | Perform → Underperform |
| 2020-03-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-08-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-07-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2018-12-04 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | 재확인 | Jefferies | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-09-21 | 재개 | Oppenheimer | Outperform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2017-09-14 | 재확인 | Piper Jaffray | Overweight |
| 2017-06-27 | 재개 | Piper Jaffray | Overweight |
| 2017-05-26 | 개시 | H.C. Wainwright | Buy |
| 2017-04-12 | 개시 | Oppenheimer | Outperform |
| 2016-11-09 | 개시 | Aegis Capital | Buy |
| 2016-10-06 | 재개 | Jefferies | Buy |
모두보기
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Vanda Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 EndofMonth & Real-Time Volume Triggers - Newser
Can Vanda Pharmaceuticals Inc. lead its sector in growthJuly 2025 Rallies & Verified Entry Point Signals - خودرو بانک
Trend analysis for Vanda Pharmaceuticals Inc. this weekWeekly Trade Summary & AI Enhanced Trade Execution Alerts - Newser
How to read the order book for Vanda Pharmaceuticals Inc.Risk Management & Free Community Consensus Stock Picks - Newser
What the charts say about Vanda Pharmaceuticals Inc. todayJuly 2025 Update & High Accuracy Swing Entry Alerts - Newser
Vanda Pharmaceuticals at Wells Fargo Conference: Strategic Growth and Innovation - Investing.com Australia
Why Vanda Pharmaceuticals Inc. is moving today2025 Price Targets & Free Real-Time Volume Trigger Notifications - Newser
Breakout Zone: What is Vanda Pharmaceuticals Inc.’s book value per shareTrade Exit Summary & Long-Term Capital Growth Ideas - خودرو بانک
How to build a dashboard for Vanda Pharmaceuticals Inc. stockEarnings Summary Report & Daily Momentum Trading Reports - Newser
Technical signs of recovery in Vanda Pharmaceuticals Inc.2025 Trading Recap & Fast Gaining Stock Strategy Reports - Newser
Multi asset correlation models including Vanda Pharmaceuticals Inc.July 2025 PreEarnings & Reliable Breakout Stock Forecasts - Newser
Vanda Pharmaceuticals Inc. stock daily chart insightsPortfolio Performance Report & Weekly Breakout Stock Alerts - Newser
How institutional ownership impacts Vanda Pharmaceuticals Inc. stock2025 Sector Review & Safe Capital Preservation Plans - Newser
Is Vanda Pharmaceuticals Inc. stock poised for growthWeekly Volume Report & Low Risk Entry Point Tips - Newser
Regression analysis insights on Vanda Pharmaceuticals Inc. performancePortfolio Value Report & Expert Approved Momentum Ideas - Newser
Is Vanda Pharmaceuticals Inc. stock showing strong momentum2025 Technical Patterns & Detailed Earnings Play Strategies - خودرو بانک
Published on: 2025-09-03 23:56:45 - Newser
Vanda at Cantor Global: Strategic Growth Amid Challenges - Investing.com
Will Vanda Pharmaceuticals Inc. price bounce be sustainablePortfolio Performance Report & Verified Chart Pattern Signals - Newser
Heatmap analysis for Vanda Pharmaceuticals Inc. and competitorsJuly 2025 Market Mood & Fast Exit Strategy with Risk Control - Newser
Should you wait for a breakout in Vanda Pharmaceuticals Inc.2025 Key Highlights & High Conviction Investment Ideas - Newser
What does recent volatility data suggest for Vanda Pharmaceuticals Inc.Portfolio Risk Summary & Verified Entry Point Signals - Newser
Key metrics from Vanda Pharmaceuticals Inc.’s quarterly dataWeekly Stock Report & Momentum Based Trading Ideas - Newser
Is Vanda Pharmaceuticals Inc. reversing from oversold territoryForecast Cut & Expert Curated Trade Ideas - Newser
Is a relief rally coming for Vanda Pharmaceuticals Inc. holdersPortfolio Growth Summary & Weekly Top Gainers Alerts - Newser
Using Bollinger Bands to evaluate Vanda Pharmaceuticals Inc.Trade Performance Summary & Fast Exit and Entry Strategy Plans - Newser
Can Vanda Pharmaceuticals Inc. benefit from deglobalizationWeekly Stock Analysis & Expert Verified Stock Movement Alerts - خودرو بانک
Portfolio Update: Is Vanda Pharmaceuticals Inc. a play on infrastructure spending2025 Price Momentum & Daily Stock Trend Watchlist - خودرو بانک
Tools to assess Vanda Pharmaceuticals Inc.’s risk profile2025 Market Outlook & Verified Swing Trading Watchlist - Newser
Using fundamentals and technicals on Vanda Pharmaceuticals Inc.Share Buyback & Capital Protection Trading Alerts - Newser
Why is Vanda Pharmaceuticals Inc. stock going upJuly 2025 Intraday Action & Weekly Sector Rotation Insights - خودرو بانک
Published on: 2025-09-01 13:55:21 - Newser
Vanda Slams US FDA ‘Generic Bias,’ Again Seeks To Undo Hetlioz ANDA Approvals - insights.citeline.com
Is Vanda Pharmaceuticals Inc. stock a smart retirement pickJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - خودرو بانک
Vanda Pharmaceuticals gets FDA orphan drug status for VGT-1849B - MSN
Vanda Pharmaceuticals Inc. recovery potential after sell offTrade Analysis Report & Expert Verified Stock Movement Alerts - Newser
Vanda Pharmaceuticals Inc (VNDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Vanda Pharmaceuticals Inc 주식 (VNDA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mitchell Stephen Ray | Director |
Jun 13 '25 |
Sale |
4.59 |
7,000 |
32,130 |
97,082 |
1.40%
자본화:
|
볼륨(24시간):